Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from biote ( (BTMD) ).
On April 3, 2026, Biote Corp. posted an updated investor presentation for April 2026 on its website, outlining its financial performance, market position and strategic highlights. The materials emphasize Biote’s leadership in hormone optimization, including 2025 revenue of $192.2 million, adjusted EBITDA of $53.5 million with a 27.8% margin, a network of more than 9,200 Biote-certified practitioners and roughly six million procedures performed for about 400,000 active patients, underscoring its scale in hormone-related healthy aging solutions.
The most recent analyst rating on (BTMD) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on biote stock, see the BTMD Stock Forecast page.
Spark’s Take on BTMD Stock
According to Spark, TipRanks’ AI Analyst, BTMD is a Neutral.
BTMD’s score is held back primarily by balance-sheet risk (negative equity) and weak technicals (below key moving averages with negative MACD). These are partially offset by improving profitability/cash generation and a very low P/E, while the latest earnings call was mixed—constructive longer-term targets and supplement growth, but near-term procedure and margin pressure.
To see Spark’s full report on BTMD stock, click here.
More about biote
Biote Corp. operates in the therapeutic wellness and healthy aging space, focusing on hormone optimization through an evidence-based, individualized and comprehensive healthcare approach. The company positions itself as an established leader in hormone optimization, supported by proprietary technology, clinical education and training, and a capital-light business model serving a large and growing addressable market.
Average Trading Volume: 219,290
Technical Sentiment Signal: Sell
Current Market Cap: $62.89M
Learn more about BTMD stock on TipRanks’ Stock Analysis page.